BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IMPAX Laboratories, Inc. (IPXL) Asks FDA for Approval of Parkinson's Drug


12/22/2011 7:31:57 AM

San Francisco Business Times by Ron Leuty, Reporter

Impax Laboratories Inc., traditionally a maker of generic drugs, submitted an application for its new treatment for Parkinson’s disease symptoms.

The Hayward company (NASDAQ: IPXL) said Wednesday that its branded products unit made the application for IPX-066 to the Food and Drug Administration.

IPX-066, an extended-release capsule formulation of carbidopa-levodopa, is being developed in collaboration with GlaxoSmithKline (NYSE: GSK) for use outside the United States and Taiwan.

If the drug is approved by the FDA, Impax would commercialize it in the United States with its own neurology sales force.

IPX-066 is meant to control jerky movements by patients with the neurodegenerative disorder by keeping levodopa in the blood longer and with more consistency than current treatments.

Impax said the drug has been studied in about 900 Parkinson’s patients.

“In just three and a half years, Impax’s brand research and development team has successfully advanced IPX-066 from an investigational new drug through multiple clinical studies of efficacy and safety, culminating in our NDA submission,” Michael Nestor, president of the Impax Pharmaceuticals unit, said in a press release.

IPX-066 has been studied in about 900 Parkinson’s disease patients.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES